Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Compounding Bill In Senate Gets Bipartisan Push For Floor Vote

This article was originally published in The Pink Sheet Daily

Executive Summary

HELP Committee leaders Harkin and Alexander write letter arguing that FDA’s warnings of more problems from tainted compounded medications have come true and that their legislation should gain a vote next month.

You may also be interested in...

Compounding/Track And Trace Bill Another Victim Of Shutdown

The stripped down version will generate considerably less user fee revenue for FDA, but so far it has met the same fate in the Senate as other recent legislation coming from the House.

Drug Prices Unaffected By Senate Supply Chain, Compounding Bill, CBO Indicates

No mention of affects to Medicare, Medicaid in the CBO score for the Senate compounding and supply chain bill, but FDA is likely to need more budget authority given that expected user fee revenues are not expected to cover the full costs of the new programs.

Compounder Definition In House Bill May Use Blended Metrics

FDA and stakeholders reiterate that volume cannot be the sole measure of whether a compounder should be regulated like a drug manufacturer; Rep. Griffith pitches potentially using it and other indicators to draw the line.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts